Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy

BMC Microbiology

Volumn 3, Issue , 2003, Pages 1-7

  Kliger, Yossef ^a   Levanon, Erez Y ^a  

^a Compugen Ltd ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C 34; CORONAVIRUS S2 PROTEIN; ENFUVIRTIDE; GLYCOPROTEIN GP 41; LEUCINE ZIPPER PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; PEPTIDE C34; PEPTIDE FRAGMENT; VIRUS FUSION PROTEIN;

AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; NONHUMAN; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; SARS CORONAVIRUS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN CONFORMATION;

CORONAVIRIDAE; CORONAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SARS CORONAVIRUS;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG DESIGN; HIV ENVELOPE PROTEIN GP41; HIV-1; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SARS VIRUS; VIRAL FUSION PROTEINS;

EID: 3042845376     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-3-20     Document Type: Article

References (23)

1. Chan DC, Fass D, Berger JM and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
2. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
3. Lu M, Blacklow SC and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995, 2: 1075-1082.
4. Salzwedel K, West JT and Hunter E: A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999, 73:2469-2480.
5. LaBonte J, Lebbos J and Kirkpatrick P: Enfuvirtide. Nature Reviews Drug Discovery 2003, 2:345.
6. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998, 93:681-684.
7. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G and Petteway S. R., Jr.: Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 1996, 93:2186-2191.
8. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C and Roper RL: The Genome sequence of the SARS-associated coronavirus. Science 2003, 300:1399-1404.
9. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ and Bellini WJ: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394-1399.
10. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK and Yuen KY: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-1325.
11. Gallaher WR and Garry RF: Model of the pre-insertion region of the spike (S2) fusion glycoprotein of the human SARS coronavirus: implications for antiviral therapeutics. [http://www.virology.net/sars/s2model.html].
12. Wild CT, Shugars DC, Greenwell TK, McDanal CB and Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994, 91:9770-9774.
13. Rapaport D, Ovadia M and Shai Y: A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. Embo J 1995, 14:5524-5531.
14. Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P and Bendinelli M: Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol 2003, 77:3724-3733.
15. Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ: Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
16. Needleman SB and Wunsch CD: A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 1970, 48:443-453.
17. Singh M, Berger B and Kim PS: LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins. J Mol Biol 1999, 290:1031-1041.
18. Tusnady GE and Simon I: The HMMTOP transmembrane topology prediction server. Bioinformatics 2001, 17:849-850.
19. Wild C, Greenwell T and Matthews T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9:1051-1053.
20. Chan DC, Chutkowski CT and Kim PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 1998, 95:15613-15617.
21. Xu Y, Zhang X, Matsuoka M and Hattori T: The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett 2000, 487:185-188.
22. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R and Shai Y: Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001, 276:1391-1397.
23. Pastey MK, Gower TL, Spearman PW, Crowe J. E., Jr. and Graham BS: A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med 2000, 6:35-40.